Consumer health products technologies solution provider Catalent has completed the biologics packaging expansion at its Bloomington facility in Indiana, US.
The company’s 875,000ft² facility in Bloomington specialises in sterile formulation and extensive bio-manufacturing and drug product fill/finish capacity in liquid and lyophilised vials, prefilled syringes, and cartridges.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The $14m expansion covers the addition of 15,000ft² packaging infrastructure to the biologics and sterile manufacturing site.
It also includes five new packaging suites and a new quality control laboratory.
The company’s strategic partnerships have led to the introduction of new technologies and integrated capabilities such as an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and a Dividella NeoTOP x (NTX) top-load cartoner with both semi-automated and fully automated configurations.
All three high-speed lines offer quick and flexible packaging solutions to customers for vials, syringes, and devices with no glass-to-glass contact.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBiologics North America region president Mike Riley said: “The completion of this expansion marks a major milestone for our late-stage and commercial customers, allowing Catalent to focus on more complex device assembly and packaging needs for biologic products at higher volumes.
“This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites.”
Headquartered in Somerset, New Jersey, Catalent has more than 40 facilities. In fiscal year 2019, it reported over $2.5bn in annual revenue.
